Skip to main content
BEACON-Neuro.AI Inc. logo

BEACON-Neuro.AI Inc.

St. Louis, Missouri, United StatesSee on the mapFounded 2026

  • Pre-Seed

BEACON-Neuro.AI develops AI imaging and risk-prediction tools to help clinicians identify stroke patients at risk of severe brain edema. Its BeaconPredict™ product analyzes admission CT imaging to support earlier, proactive treatment decisions.

Raised
$35.2M
Aug 2026
Pre-Seed
Investors
3
Founded
2026
Employees
1–10

reccy insights

Recent highlights

BEACON-Neuro.AI's stated product focus is BeaconPredict™, an AI tool designed to use admission CT imaging to predict malignant cerebral edema after stroke. Its funding history lists a $32 million Series A on Mar 2, 2026, with Geodesic Capital and Costanoa Ventures named as lead investors. Two additional rounds are listed later in the year: a $2.7 million Seed round led by Point72 Ventures on Aug 27, 2026 and a $500,000 Pre-Seed round on Aug 28, 2026. These entries do not reconcile with the stated $32 million total funding figure, and the round sequence is unusual, so the individual amounts should be considered separately from the total. The company’s current milestone evidence therefore centers on its stroke-imaging product, its stated regulatory designation, and the listed financing activity.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes BEACON-Neuro.AI Inc. distinct

  1. 01Targets the critical stroke-care problem of identifying patients at risk of severe brain edema before they deteriorate.
  2. 02Uses admission CT imaging to generate patient-specific risk insights.
  3. 03Aims to give clinicians an opportunity to act before edema causes irreversible neurological damage.
  4. 04The company describes its team as spanning neurology, neurocritical care, neurosurgery, radiology, and business development.

Technology & products

  • BeaconPredict™

    AI-powered analysis of admission CT imaging to predict malignant cerebral edema after stroke and support earlier clinical decisions.

  • BeaconPredict™ analyzes admission CT imaging to predict post-stroke malignant cerebral edema.

Research roots1

Labs and research groups this company came from or works with.

  • Washington University in St. LouisSt Louis, United States · No page yet
    Other link
Academic data: Carter Sciences

Funding

$35.2M disclosed
  • Pre-SeedAug 2026
    $500K
  • SeedAug 2026
    $2.7MLed by Point72 Ventures
  • Series AMar 2026
    $32MLed by Geodesic Capital, Costanoa Ventures
3 investors

Investors3

Also backed by
  • Geodesic Capital
  • Costanoa Ventures

About BEACON-Neuro.AI Inc.

Products
BeaconPredict™
Leadership
Daniel Marcus
Focus areas
AI, digital health, stroke care, medical imaging, neurocritical care, clinical decision support, risk prediction
Headquarters
St. Louis, Missouri, United States
Founded
2026
Employees
1–10